Jennifer Friedmann

417 total citations
16 papers, 157 citations indexed

About

Jennifer Friedmann is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Immunology. According to data from OpenAlex, Jennifer Friedmann has authored 16 papers receiving a total of 157 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Oncology, 7 papers in Pulmonary and Respiratory Medicine and 3 papers in Immunology. Recurrent topics in Jennifer Friedmann's work include HER2/EGFR in Cancer Research (5 papers), Cancer Immunotherapy and Biomarkers (5 papers) and COVID-19 and healthcare impacts (4 papers). Jennifer Friedmann is often cited by papers focused on HER2/EGFR in Cancer Research (5 papers), Cancer Immunotherapy and Biomarkers (5 papers) and COVID-19 and healthcare impacts (4 papers). Jennifer Friedmann collaborates with scholars based in Canada, United States and Spain. Jennifer Friedmann's co-authors include Wilson H. Miller, Victor Cohen, Khalil Sultanem, Jason Agulnik, Goulnar Kasymjanova, Carmela Pepe, Kelly A. Pike, Michael J. H. Ratcliffe, Alan Spatz and Lama Sakr and has published in prestigious journals such as Journal of Clinical Oncology, The Journal of Immunology and Cancer Research.

In The Last Decade

Jennifer Friedmann

15 papers receiving 154 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Jennifer Friedmann Canada 6 108 58 40 21 20 16 157
Almut Mecke Switzerland 6 105 1.0× 40 0.7× 35 0.9× 62 3.0× 11 0.6× 10 150
Tom Ferguson Australia 7 73 0.7× 64 1.1× 21 0.5× 46 2.2× 49 2.5× 20 161
Aleigha Lawless United States 4 179 1.7× 54 0.9× 43 1.1× 14 0.7× 48 2.4× 21 218
Urbano Anido Herranz Spain 5 144 1.3× 104 1.8× 14 0.3× 90 4.3× 28 1.4× 16 203
Igor Lifirenko Russia 4 118 1.1× 83 1.4× 22 0.6× 34 1.6× 40 2.0× 4 182
Meera Patel United States 6 81 0.8× 56 1.0× 20 0.5× 29 1.4× 15 0.8× 15 127
Jorge Daza United States 7 42 0.4× 49 0.8× 40 1.0× 101 4.8× 55 2.8× 21 166
Hamadi Almotlak France 8 78 0.7× 75 1.3× 10 0.3× 14 0.7× 31 1.6× 19 134
Yu Yu China 5 139 1.3× 60 1.0× 53 1.3× 15 0.7× 32 1.6× 6 197
Rita Leporati Italy 7 140 1.3× 46 0.8× 16 0.4× 9 0.4× 21 1.1× 16 188

Countries citing papers authored by Jennifer Friedmann

Since Specialization
Citations

This map shows the geographic impact of Jennifer Friedmann's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jennifer Friedmann with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jennifer Friedmann more than expected).

Fields of papers citing papers by Jennifer Friedmann

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jennifer Friedmann. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jennifer Friedmann. The network helps show where Jennifer Friedmann may publish in the future.

Co-authorship network of co-authors of Jennifer Friedmann

This figure shows the co-authorship network connecting the top 25 collaborators of Jennifer Friedmann. A scholar is included among the top collaborators of Jennifer Friedmann based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jennifer Friedmann. Jennifer Friedmann is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

16 of 16 papers shown
1.
Meric‐Bernstam, Funda, Martin Gutierrez, Enrique Sanz‐García, et al.. (2025). Phase 2 Study of Zilovertamab Vedotin in Participants with Metastatic Solid Tumors. Cancer Research Communications. 5(9). 1664–1673. 1 indexed citations
2.
3.
4.
Dankner, Matthew, Victor Cohen, Lawrence Panasci, et al.. (2024). The Real-World Clinical Outcomes of Heavily Pretreated HER2+ and HER2-Low Metastatic Breast Cancer Patients Treated with Trastuzumab Deruxtecan at a Single Centre. Current Oncology. 32(1). 1–1. 3 indexed citations
5.
Agulnik, Jason, Goulnar Kasymjanova, Carmela Pepe, et al.. (2024). Real-World Evidence of the Impact of the COVID-19 Pandemic on Lung Cancer Survival: Canadian Perspective. Current Oncology. 31(3). 1562–1571. 1 indexed citations
6.
Escrivá-de-Romaní, Santiago, Juan Miguel Cejalvo, Emilio Alba, et al.. (2024). Abstract LBO1-04: Primary results from a phase 2a study of zanidatamab (zani) + palbociclib (palbo) + fulvestrant (fulv) in HER2+/HR+ metastatic breast cancer (mBC). Cancer Research. 84(9_Supplement). LBO1–4. 3 indexed citations
7.
Kasymjanova, Goulnar, Carmela Pepe, Jennifer Friedmann, et al.. (2022). The longitudinal impact of COVID-19 on the diagnosis and treatment of lung cancer at a Canadian academic center: Interim analysis from a retrospective chart review.. Journal of Clinical Oncology. 40(16_suppl). e18737–e18737.
8.
Kasymjanova, Goulnar, Carmela Pepe, Jennifer Friedmann, et al.. (2022). The Impact of COVID-19 on the Diagnosis and Treatment of Lung Cancer over a 2-Year Period at a Canadian Academic Center. Current Oncology. 29(11). 8677–8685. 8 indexed citations
9.
Kasymjanova, Goulnar, Victor Cohen, Khalil Sultanem, et al.. (2021). The Impact of COVID-19 on the Diagnosis and Treatment of Lung Cancer at a Canadian Academic Center: A Retrospective Chart Review. Current Oncology. 28(6). 4247–4255. 33 indexed citations
10.
Miller, Wilson H., Rahima Jamal, Eftihia Cocolakis, et al.. (2018). Systemic immune signature of inflammation in metastatic melanoma (MM) patients treated with ipilimumab (IPI) and carboplatin/paclitaxel (CP).. Journal of Clinical Oncology. 36(5_suppl). 185–185. 1 indexed citations
11.
Jamal, Rahima, Réjean Lapointe, Eftihia Cocolakis, et al.. (2017). Peripheral and local predictive immune signatures identified in a phase II trial of ipilimumab with carboplatin/paclitaxel in unresectable stage III or stage IV melanoma. Journal for ImmunoTherapy of Cancer. 5(1). 83–83. 38 indexed citations
12.
Jamal, Rahima, Léon C.L.T. van Kempen, Paméla Thébault, et al.. (2015). One-year overall survival (OS) and biomarker correlates from a phase II study of ipilimumab (IPI) with carboplatin and paclitaxel (CP) in patients with unresectable stage III or IV metastatic melanoma (MM).. Journal of Clinical Oncology. 33(15_suppl). 9062–9062. 1 indexed citations
13.
Jamal, Rahima, Karl Bélanger, Jennifer Friedmann, et al.. (2014). A randomized phase II study of ipilimumab (IPI) with carboplatin and paclitaxel (CP) in patients with unresectable stage III or IV metastatic melanoma (MM).. Journal of Clinical Oncology. 32(15_suppl). 9066–9066. 7 indexed citations
14.
Friedmann, Jennifer, et al.. (2011). INCREASING RELIABILITY AND INFORMATION CONTENT OF PULSE OXIMETRIC SAHS SCREENING ALGORITHMS. 438–445. 2 indexed citations
15.
Goss, Glenwood, Hal W. Hirte, Wilson H. Miller, et al.. (2005). A phase I study of oral ZD 1839 given daily in patients with solid tumors: IND.122, a study of the Investigational New Drug Program of the National Cancer Institute of Canada Clinical Trials Group. Investigational New Drugs. 23(2). 147–155. 35 indexed citations
16.
Pike, Kelly A., et al.. (2004). The Cytoplasmic Domain of Igα Is Necessary and Sufficient to Support Efficient Early B Cell Development. The Journal of Immunology. 172(4). 2210–2218. 21 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Almut Mecke Breakdown of academic impact, for papers by Tom Ferguson Breakdown of academic impact, for papers by Aleigha Lawless Breakdown of academic impact, for papers by Urbano Anido Herranz Breakdown of academic impact, for papers by Igor Lifirenko Breakdown of academic impact, for papers by Meera Patel Breakdown of academic impact, for papers by Jorge Daza Breakdown of academic impact, for papers by Hamadi Almotlak Breakdown of academic impact, for papers by Yu Yu Breakdown of academic impact, for papers by Rita Leporati
Rankless by CCL
2026